Shanghai Henlius Biotech
BiotechShanghai, China, China · Est. 2010
Shanghai Henlius Biotech is a biopharmaceutical company focused on developing innovative monoclonal antibodies and recombinant proteins for the treatment of cancer, immunological diseases, and other conditions.
25
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
24
Indications↗
Distinct diseases across all programs
123
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
25 drugs in development
Phase 39
Phase 27
Phase 18
By Therapeutic Area
top 2
Oncology
2489%
Metabolic & Endocrine
14%
R&D Momentum
75/100
Pipeline Velocity
49/100
Trial Completion Rate
80/100
Pipeline Concentration
80/100
Pipeline Freshness
71/100
Strategic Signals
- ↗Active in Metabolic & Endocrine but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Jul 9, 2026
Recruiting
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 (DLL3 × DLL3 × CD3 × CD28 Tetra-specific Antibody) in Patients With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma
Jul 3, 2026
Recruiting
A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX48 (EGFR/c-MET Bispecific Antibody-Drug Conjugate) in Participants With Advanced/Metastatic Solid Tumors
Earlier
May 27, 2026TrialA Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
May 14, 2026TrialA Study to Evaluate the Safety, PK, and Immunogenicity of Recombinant Human Hyaluronidase in Healthy Subjects
Apr 25, 2026TrialPhase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.
Apr 9, 2026TrialA Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
Apr 1, 2026TrialA Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Mar 1, 2026TrialPhase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid Tumor
4 more events
Mar 1, 2026TrialA Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer
Feb 27, 2026TrialA Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
Jan 31, 2026TrialA Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal Cancer
Jan 27, 2026TrialA Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat Cancer
Details
Company Info
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Therapeutic Focus
oncologyimmunologyophthalmology
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Metabolic & Endocrine(1 drug)
—
1
1
—
—
Metabolic & Endocrine(1 drug)
Oncology(24 drugs)
—
7
6
15
—
Oncology(24 drugs)
Unknown / Other(2 drugs)
—
1
1
—
—
Unknown / Other(2 drugs)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)